AbCellera Biologics Inc header image

AbCellera Biologics Inc

ABCL

Equity

ISIN null / Valor 58489933

NASDAQ (2026-11-09)
USD 12.50+5.22%

AbCellera Biologics Inc
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

AbCellera Biologics Inc. is a Vancouver-based biotechnology company that develops and commercializes technologies to discover and optimize therapeutic antibodies, combining high-throughput single‑cell screening, microfluidics, next‑generation sequencing and machine‑learning analytics to identify promising human antibodies from patient samples; it works with pharmaceutical and biotech partners under research collaborations, licensing and co‑development agreements, generating revenue from upfront fees, research payments, milestones and potential royalties. The firm positions its platform to accelerate programs across infectious disease, oncology and immunology, and gained public attention for its role in identifying a COVID‑19 therapeutic antibody developed with a pharmaceutical partner. AbCellera is publicly traded and operates as a service and platform provider to companies seeking to shorten antibody discovery timelines rather than as a classical drug commercializer.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

220%1Y
209%3Y
-15.0%5Y

Performance

83.2%1Y
72.7%3Y
68.6%5Y

Volatility

Market cap

3833 M

Market cap (USD)

Daily traded volume (Shares)

2,999,372

Daily traded volume (Shares)

1 day high/low

2.95 / 2.795

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
3.00
Innovation:
starstarstarstarstar
3.00
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
3.00
Marcel Oenning
Switzerland, 28 Mar 2025
star star star star star
Potenzial

EQUITIES OF THE SAME SECTOR

Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.52%GBP 16.25
Beximco Pharmaceuticals Ltd
Beximco Pharmaceuticals Ltd Beximco Pharmaceuticals Ltd Valor: 2318407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.17%GBP 0.63
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.06%EUR 67.40
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.32%SEK 496.60
Metropolis Healthcare Ltd.
Metropolis Healthcare Ltd. Metropolis Healthcare Ltd. Valor: 11536062
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.20%INR 581.80
Quest Diagnostics Inc
Quest Diagnostics Inc Quest Diagnostics Inc Valor: 566162
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.58%USD 259.67
Ajanta Pharma Limited
Ajanta Pharma Limited Ajanta Pharma Limited Valor: 27480449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.02%INR 3,341.25
Interparfums Inc
Interparfums Inc Interparfums Inc Valor: 833467
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%USD 136.16
Staar Surgical Co
Staar Surgical Co Staar Surgical Co Valor: 972813
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.62%USD 24.55
PTC Therapeutics Inc
PTC Therapeutics Inc PTC Therapeutics Inc Valor: 2515234
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.63%USD 65.03